Mitsikostas Dimos D, Belesioti Ioanna, Arvaniti Chryssa, Mitropoulou Euthymia, Deligianni Christina, Kasioti Elina, Constantinidis Theodoros, Dermitzakis Manolis, Vikelis Michail
First Neurology Department, Aeginition Hospital, School of Medicine, National & Kapodistrian University of Athens, 72-74 V. Sofias' Avenue, 11528, Athens, Greece.
Second Neurology Department, Attikon Hospital, School of Medicine, National & Kapodistrian University of Athens, Athens, Greece.
J Headache Pain. 2017 Oct 6;18(1):102. doi: 10.1186/s10194-017-0813-3.
We aimed to explore patients' preferences for headache treatments with a self-administered questionnaire including the Q-No questionnaire for nocebo.
Questionnaires from 514 outpatients naïve to neurostimulation and monoclonal antibodies were collected.
Patients assessed that the efficacy of a treatment is more important than safety or route of administration. They preferred to use an external neurostimulation device for both acute (67.1%) and preventive treatment (62.8%). Most patients preferred to take a pill (86%) than any other drug given parenterally for symptomatic pharmaceutical treatment. For preventive pharmaceutical treatment, most patients preferred to take a pill once per day (52%) compared to an injection either subcutaneously or intravenously each month (9% and 4%), or three months (15% and 11%). 56.6% of all participants scored more than 15 in Q-No questionnaire indicating potential nocebo behaviors that contributed significantly in their choices.
These patient preferences along with efficacy and safety data may help physicians better choose the right treatment for the right person.
我们旨在通过一份自我管理问卷，包括用于反安慰剂效应的Q-No问卷，来探究患者对头痛治疗方法的偏好。
收集了514名未接受过神经刺激和单克隆抗体治疗的门诊患者的问卷。
患者评估认为治疗效果比安全性或给药途径更重要。他们更倾向于使用外部神经刺激设备进行急性治疗（67.1%）和预防性治疗（62.8%）。对于症状性药物治疗，大多数患者更喜欢口服药物（86%），而非任何其他胃肠外给药方式。对于预防性药物治疗，大多数患者更喜欢每日口服一次（52%），相比之下，每月皮下或静脉注射（分别为9%和4%）或每三个月注射一次（分别为15%和11%）的比例较低。在所有参与者中，56.6%在Q-No问卷中的得分超过15分，表明存在潜在的反安慰剂行为，这在他们的选择中起到了重要作用。
这些患者偏好以及疗效和安全性数据可能有助于医生更好地为合适的患者选择正确的治疗方法。
